Research Analysts Set Expectations for MLYS Q3 Earnings

Key Points

• HC Wainwright has raised its earnings per share estimate for Mineralys Therapeutics for Q3 2025 from ($0.92) to ($0.74) and maintains a "Buy" rating with a price target of $42.00.
• The stock currently holds an average rating of "Hold" among analysts, with a consensus target price of $32.25.
• In the last quarter, insiders sold 123,051 shares of the company's stock, indicating a decrease in insider ownership, which currently stands at 25.56%.

Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) - Analysts at HC Wainwright upped their Q3 2025 earnings estimates for Mineralys Therapeutics in a report released on Wednesday, August 13th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings of ($0.74) per share for the quarter, up from their previous forecast of ($0.92). HC Wainwright currently has a "Buy" rating and a $42.00 price target on the stock. The consensus estimate for Mineralys Therapeutics' current full-year earnings is ($4.23) per share. HC Wainwright also issued estimates for Mineralys Therapeutics' Q4 2025 earnings at ($0.82) EPS, FY2025 earnings at ($3.01) EPS, FY2026 earnings at ($2.85) EPS, FY2027 earnings at ($3.00) EPS, FY2028 earnings at ($1.20) EPS and FY2029 earnings at $1.72 EPS.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.12.

Several other equities research analysts have also commented on MLYS. Guggenheim set a $48.00 price objective on shares of Mineralys Therapeutics and gave the stock a "buy" rating in a research note on Wednesday, May 14th. Wall Street Zen lowered shares of Mineralys Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, June 14th. Finally, Jefferies Financial Group started coverage on shares of Mineralys Therapeutics in a research note on Tuesday, June 10th. They set a "hold" rating and a $15.00 price objective on the stock. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $32.25.

Mineralys Therapeutics Price Performance

NASDAQ:MLYS traded down $0.87 during mid-day trading on Friday, hitting $14.47. 1,173,594 shares of the company's stock were exchanged, compared to its average volume of 880,427. Mineralys Therapeutics has a one year low of $8.24 and a one year high of $18.38. The business has a fifty day moving average price of $14.03 and a 200 day moving average price of $13.61. The company has a market cap of $959.29 million, a PE ratio of -4.06 and a beta of -0.29.

Insider Transactions at Mineralys Therapeutics

In other news, insider David Malcom Rodman sold 11,366 shares of the company's stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $14.59, for a total value of $165,829.94. Following the transaction, the insider owned 97,907 shares in the company, valued at approximately $1,428,463.13. This represents a 10.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Adam Scott Levy sold 59,925 shares of the stock in a transaction that occurred on Wednesday, July 30th. The shares were sold at an average price of $14.76, for a total transaction of $884,493.00. Following the transaction, the chief financial officer owned 132,934 shares in the company, valued at approximately $1,962,105.84. This trade represents a 31.07% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 123,051 shares of company stock worth $1,776,262. Corporate insiders own 25.56% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MLYS. Vanguard Group Inc. lifted its position in Mineralys Therapeutics by 5.0% during the fourth quarter. Vanguard Group Inc. now owns 1,432,042 shares of the company's stock valued at $17,628,000 after purchasing an additional 68,811 shares during the period. JPMorgan Chase & Co. lifted its position in Mineralys Therapeutics by 2,251.5% during the fourth quarter. JPMorgan Chase & Co. now owns 503,590 shares of the company's stock valued at $6,199,000 after purchasing an additional 482,174 shares during the period. Wells Fargo & Company MN lifted its position in Mineralys Therapeutics by 19.1% during the fourth quarter. Wells Fargo & Company MN now owns 23,714 shares of the company's stock valued at $292,000 after purchasing an additional 3,802 shares during the period. Renaissance Technologies LLC increased its holdings in Mineralys Therapeutics by 15.1% during the fourth quarter. Renaissance Technologies LLC now owns 119,500 shares of the company's stock valued at $1,471,000 after buying an additional 15,700 shares during the last quarter. Finally, Barclays PLC increased its holdings in Mineralys Therapeutics by 21.4% during the fourth quarter. Barclays PLC now owns 46,396 shares of the company's stock valued at $571,000 after buying an additional 8,178 shares during the last quarter. Institutional investors own 84.46% of the company's stock.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.